Details checkedClinical trial listing onlyCheckedregistry

Truway Health HEAR-RESTORE exploratory inner-ear regenerative study

Also known as: Truway Health HEAR-RESTORE Regenerative Study, HEAR-RESTORE, TH-PRS-IEAR-2026-001, NCT07472023

Truway Health, Inc.

Primary source

Company

Truway Health, Inc.

Program Type

Therapeutic

Modality

Regenerative Medicine

Stage

Phase 1

Status

Active

Target Gene

—

Route / Mode

Unspecified investigational regenerative interventions

Confidence

68%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

United States

Population

adult, tinnitus, sensorineural, noise-induced, sudden, regenerative-medicine

Trial IDs

Mechanism

Exploratory study describing broad investigational regenerative pharmacologic, stem-cell, and combination therapy concepts for inner-ear injury, tinnitus, and sensorineural hearing loss; specific product composition is not disclosed in the registry.

Indications

Hearing Loss Sensorineural Hearing Loss Tinnitus Sudden Hearing Loss Noise-Induced Hearing Loss

Notes

Verified only as a Truway-sponsored registry study record. ClinicalTrials.gov lists HEAR-RESTORE as enrolling by invitation, but the intervention descriptions are broad, product composition is unspecified, and completion dates extend to 2099. Present this as a low-confidence study-level record, not as a validated therapeutic product program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, stage, status, indications...

IDs: NCT07472023, HEAR-RESTORE, TH-PRS-IEAR-2026-001

Open

Key Events

2026-03-16

HEAR-RESTORE exploratory regenerative study first posted

Clinical Trials (1)

NCT07472023

Data Checks